Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

 

Search in our Online Store

RENTSCHLER focuses on biotechnology and sells RENTSCHLER Pharma GmbH Print E-mail
09 Jul 2008

RENTSCHLER will invest another 14 million Euro in the expansion of RENTSCHLER Biotechnologie GmbH at the Laupheim site

Laupheim, Germany | July 9, 2008 | RENTSCHLER will invest another 14 million Euro in the expansion of RENTSCHLER Biotechnologie GmbH at the Laupheim site. Only recently a 50 million Euro investment in biotechnological development and production facilities was completed.

The first sod will already be taken this year for the new construction of a logistics centre and the expansion of the administrative building in Erwin-Rentschler-Straße in Laupheim.

In the logistics centre a high-rise warehouse, several cold warehouses, an incoming goods department, a dispatch area and the company's transport fleet will be located. The move into the new buildings is planned for end of 2009.
With this step, Rentschler concentrates all of the biotech activities at one site and thus provides the frame for further growth.

Within the scope of this business concentration on the development and manufacture of biopharmaceutical drug products Dr. RENTSCHLER Holding GmbH & Co. KG has sold as per today all of the shares of RENTSCHLER Pharma GmbH to RIEMSER Arzneimittel AG in Greifswald/Isle of Riems, Eastern Germany.

RIEMSER is planning to further expand its business division contract manufacture from the Laupheim site. In this connection RENTSCHLER Pharma GmbH will be renamed to RIEMSER Speciality Production GmbH.

RENTSCHLER Biotechnologie GmbH is an internationally operating contract organisation with many years of experience in the development, production and registration of drug products based on biopharmaceutical drug substances. The range of services of RENTSCHLER Biotechnologie GmbH also comprises the sterile filling of pre-filled syringes and injection vials. In Germany, the company employs more than 400 people.

The company RENTSCHLER, founded in 1927, concentrates its activities on the business sector biotechnology. RENTSCHLER Biotechnologie GmbH is a subsidiary of the medium-sized family-owned business Dr. RENTSCHLER Holding GmbH & Co. KG headquartered Laupheim, Baden-Wurttemberg, Germany.

SOURCE: Rentschler Biotechnologie GmbH





Digg!Reddit!Del.icio.us!Google!Live!Facebook!Slashdot!Netscape!Technorati!StumbleUpon!Spurl!Wists!Simpy!Newsvine!Blinklist!Furl!Fark!Blogmarks!Yahoo!Smarking!Netvouz!Shadows!RawSugar!Ma.gnolia!PlugIM!Squidoo!BlogMemes!FeedMeLinks!BlinkBits!Tailrank!linkaGoGo!Free social bookmarking plugins and extensions for Joomla! websites! title=
 

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Enzyme Replacement Therapies

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics